Abstract
Purpose
We describe the clinico-pathologic and mammographic characteristics of inflammatory breast cancer (IBC) and non-IBC cases enrolled in a case–control study. Because IBC is a clinico-pathologic entity with rapid appearance of erythema and other signs, its diagnosis is based on clinical observation and thus, by necessity, subjective. Therefore, we evaluate our cases by photographic review by outside expert clinicians and by degree of adherence to the two most recent definitions of IBC: the international expert panel consensus statement and American Joint Committee on Cancer (AJCC) 8th edition (we used the slightly less restrictive 7th edition definition for our study).
Methods
We enrolled 267 IBC and 274 age- and geographically matched non-IBC cases at 6 sites in Egypt, Tunisia, and Morocco in a case–control study of IBC conducted between 2009 and 2015. We collected clinico-pathologic and mammographic data and standardized medical photographs of the breast.
Results
We identified many differences between IBC and non-IBC cases: 54.5% versus 68.8% were estrogen receptor-positive, 39.9% versus 14.8% human epidermal growth factor receptor 2-positive, 91% versus 4% exhibited erythema, 63% versus 97% had a mass, and 57% versus 10% had mammographic evidence of skin thickening. Seventy-six percent of IBC cases adhered to the expert panel consensus statement and 36% to the AJCC definition; 86 percent were confirmed as IBC by either photographic review or adherence to the consensus statement.
Conclusions
We successfully identified distinct groups of IBC and non-IBC cases. The reliability of IBC diagnosis would benefit from expert review of standardized medical photographs and associated clinical information.
Similar content being viewed by others
References
Edge S, Byrd D, Compton C et al (2010) Breast. In: Edge S, Byrd D, Compton C et al (eds) AJCC cancer staging manual, 7th edn. Springer, New York, pp 345–376
Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR (eds) (2017) AJCC cancer staging manual, 8th edn. Springer, New York
Walshe JM, Swain SM (2005–2006) Clinical aspects of inflammatory breast cancer. Breast Dis 22:35–44
Anderson WF, Chu KC, Chang S (2003) Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol 21:2254–2259
Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97:966–975
Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH (2005–2006) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9–23
Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M (2011) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22:515–523
Soliman AS, Schairer C (2012) Considerations in setting up and conducting epidemiologic studies of cancer in middle- and low-income countries: the experience of a case-control study on inflammatory breast cancer in North Africa in the past 10 years. Cancer Med 1:338–349
Schairer C, Soliman AS, Omar S, Khaled H, Eissa S, Ayed FB, Khalafallah S, Ayoub WB, Kantor ED, Merajver S, Swain SM, Gail M, Brown LM (2013) Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia. Cancer Med 2:178–184
Boussen H, Bouzaiene H, Hassouna JB, Gamoudi A, Benna F, Rahal K (2008) Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features. Semin Oncol 35:17–24
Soliman AS, Kleer CG, Mrad K, Karkouri M, Omar S, Khaled HM, Benider A-L, Ben Ayed F, Eissa SS, Eissa MS, McSpadden EJ, Lo A-C, Toy K, Kantor ED, Xiao Q, Hampton C, Merajver SD (2011–2012) Inflammatory breast cancer in North Africa: comparison of clinical and molecular epidemiologic characteristics of patients from Egypt, Tunisia, and Morocco. Breast Dis 33:159–169
Slaoui M, Zoure AA, Mouh FZ, Bensouda Y, El Mzibri M, Bakri Y, Amrani M (2018) Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO). BMC Cancer 18:713
Chaher N, Arias-Pulido H, Terki N, Qualls C, Bouzid K, Verschraegen C, Wallace AM, Royce M (2012) Molecular and epidemiologic characteristics of inflammatory breast cancer in Algerian patients. Breast Cancer Res Treat 131:437–444
Labidi SI, Mrad K, Mezlini A, Ouarda MA, Combes JD, Abdallah MB, Romdhane KB, Viens P, Ben Ayed F (2008) Inflammatory breast cancer in Tunisia in the era of multimodality therapy. Ann Oncol 19:473–480
Matro JM, Li T, Cristofanilli M, Hughes ME, Ottesen RA, Weeks JC, Wong Y-U (2015) Inflammatory breast cancer management in the National Comprehensive cancer network: the disease, recurrence pattern, and outcome. Clin Breast Cancer 15:1–7
Dabi Y, Darrigues L, Pons K, Mabille M, Abd Alsamad I, Mitri R, Skalli D, Haddad B, Touboul C (2017) Incidence of inflammatory breast cancer in patients with clinical inflammatory breast symptoms. PLoS ONE 12(12):e0189385. https://doi.org/10.1371/journal.pone.0189385
Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, Resetkova E, Hortobagyi GN, Cristofanilli M (2008) Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 109:417–426
Levine PH, Portera CC, Hoffman HJ, Yang SX, Takikita M, Duong QN, Hewitt SM, Swain SM (2012) Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and e-cadherin in distinguishing inflammatory from locally advanced breast cancer. Clin Breast Cancer 12:232–239
Lê MG, Arriagada R, Contesso G, Cammoun M, Pfeiffer F, Tabbane F, Bahi J, Dilaj M, Spielmann M, Travagli J-P, Tursz Mourali N (2005) Dermal lymphatic emboli in inflammatory and noninflammatory breast cancer: a French-Tunisian joint study in 337 patients. Clin Breast Cancer 6:439–445
Günhan-Bilgen I, Üstün EE, Memiş A (2002) Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases. Radiology 223:829–838
Snedecor GW, Cochran WG (1980) Statistical Methods, 7th edn. The Iowa State University Press, Ames
Van Uden DJP, van Laarhoven HWM, Westenberg AH, deWilt JHW, Blanken-Peeters CFJM (2015) Inflammatory breast cancer: an overview. Crit Rev Oncol/Hematol 93:116–126
Chow CK (2005–2006) Imaging in inflammatory breast carcinoma. Breast Dis 22:45–54
Levine PH, Zolfaghari L, Young H, Hafi M, Cannon T, Ganesan C, Veneroso C, Brem R, Sherman M (2010) What is inflammatory breast cancer? Revisiting the case definition. Cancers 2:143–152
Le L, Schairer C, Hablas A, Meza J, Watanabe-Galloway S, Ramadan M, Merajver SD, Seifeldin IA, Soliman AS (2017) Reliability of medical records in diagnosing inflammatory breast cancer in Egypt. BMC Res Notes 10:126
Shah NM, Soliman AS, Benerjee M, Merajver SD, Ismail K, Seifeldin I, Hablas A, Zarzour A, Abdel Aziz A, Ben Ayed F, Chamberlain RM (2006) Knowledge gained after a brief CME moduel on breast cancer diagnosis. J Cancer Educ 3:169–174
Ueno NT, Fernandez JRE, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WA (2018) International consensus on the clinical management of inflammatory breast cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th anniversary conference. J Cancer 9:1437–1447
Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M (1989) Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64(9):1941–1951
Acknowledgements
We are very grateful to the women who participated in this study. We also thank the following individuals for their important contributions to the study, including identifying, enrolling, and interviewing study subjects, study management, data keying, logistical support, and translation: Tanta Cancer Center/Gharbiah Cancer Society: Dr. Salwas Samir, Dr. Eman Sobhy, Dr. Mohammed El Kholy, Mr. Khalid Dabboos, Ms. Hanaa Elmenshawy; NCI Cairo: Dr. Gamal Amira, Dr. Ahmed El Bastawisy, Dr. Heba Mohamed El Leethy, Dr. Usama Farouk El Nagar, Dr. Maha Yehia, Ms. Walaa Emara, Ms. Magda Hassan, Ms. Hanan Mabrouk; Institute Salah Azaiz: Dr. Karima Mrad, Dr. Dalenda Hentati, Dr. Houda Belfekih, Dr. Nesrine Chraiet, Dr. Amira Daldoul, Dr. Mouna Ayadi, Dr. Bassem Alani, Ms. Leila Fadhlaoui, Ms. Neila Ben Hassen; Ibn Rochd Oncology Center: Prof. Nadia Benchakroun, Dr. Hoda Eddakaoui, Dr. Myriam Hatime, Dr. Soufya Majdoul, Dr. Fadwa Qachach, Dr. Basma Billal, Dr. Hajar Kouss, Dr. Noureddine Matar, Dr. Iman Meziane, Dr. Sara Belkheiri, Dr. Karima Bendahhou, Dr. Majdouline Khounigere, Dr. Ibrahim Khalil Ahmadaye; University Hospital Center Mohammed VI: Dr. Mariam Affane, Dr. Sana Zabroug, Dr. Mouna Darfaoui, Mr. Hicham Jabraoui; IMS (data management and keying): Ms. Leslie Carroll, Mr. Bob Banks, Ms. Bette Griffith, Dr. Carol Giffen, Mr. Michael Spriggs; NCI-USA (logistical support): Mr. David Check, Ms. Prisca N. Fall; Westat (translation): Ms. Susan Crystal-Mansour, Ms. Jerelyn Bouic. The National Institutes of Health National Library of Medicine Interaction Tool used in this work was developed by the Communications Engineering Branch of the National Library of Medicine (Mr. Rodney Long and Mr. Leif Neve). We would also like to thank the CEESP students who assisted in different parts of the study during their CEESP projects.
Funding
The National Cancer Institute Intramural Research Program (CS), the Breast Cancer Research Foundation (SDM), the Metavivor Foundation (SDM), The Cancer Epidemiology Education in Special Populations (CEESP) Program—Grant R25 CA112383 (ASS).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Sandra Swain reports receiving honoraria from Novartis, personal fees from Cardinal Health, Daiichi-Sankyo, Eli Lilly & Co., Genentech/Roche, Genomic Health, Inivata, Peiris Pharmaceuticals, Tocagen; research support from Genentech; travel and accommodations from Caris Centers of Excellence, Daiichi-Sankyo, Eli Lilly & Co., Genentech/Roche, NanoString Technologies; and remuneration from AstraZeneca for participation on OlympiA IDMC. The other authors declare they have no conflicts of interest.
Ethical approval
All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committees.
Informed consent
Informed consent was obtained from all study participants.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Schairer, C., Hablas, A., Eldein, I.A.S. et al. Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa. Breast Cancer Res Treat 176, 407–417 (2019). https://doi.org/10.1007/s10549-019-05237-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-019-05237-5